Trials / Completed
CompletedNCT05136677
A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants
A Phase II, Randomized, Open-label Trial of Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin as First-line Therapy for Unresectable Pleural Mesothelioma in Chinese Participants
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 102 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the efficacy and safety of the combination of nivolumab and ipilimumab in Chinese participants with malignant pleural mesothelioma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Nivolumab | Specified dose on specified days |
| BIOLOGICAL | Ipilimumab | Specified dose on specified days |
| DRUG | Pemetrexed | Specified dose on specified days |
| DRUG | Cisplatin | Specified dose on specified days |
| DRUG | Carboplatin | Specified dose on specified days |
Timeline
- Start date
- 2022-01-25
- Primary completion
- 2025-11-12
- Completion
- 2025-11-12
- First posted
- 2021-11-29
- Last updated
- 2026-01-23
Locations
21 sites across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05136677. Inclusion in this directory is not an endorsement.